CStone Pharma's (基石药业) Lock-Up Expiry - Analysis of Potential Selling Shareholders
Lock-up restriction for Cstone Pharma's pre-IPO investors and cornerstone investors will expire on August 26th. As we expect roughly USD 1 billion...
469 Views
China Biotech: Read-Through from Opdivo/Keytruda's Recent Failures (Liver Cancer & Gastric Cancer)
BMS recently reported failed Phase III clinical trial for Opdivo, one of two leading anti-PD-1 (programmed cell death protein 1) monoclonal...
415 Views
Junshi Bioscience Lock-Up Expiry: Valuation Still Rich with Few R&D Updates
Shanghai Junshi Bioscience Co. Ltd. (1877 HK) was listed on December 2018 and recorded a stellar debut performance thanks to the NDA approval for...
421 Views
Shanghai Henlius (复宏汉霖) IPO: Valuation of Four Biosimilars
Shanghai Henlius, a clinical-stage pharmaceutical company back by Fosun Pharma, is seeking a listing in Hong Kong. In our previous insight, we have...
885 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
584 Views